spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  bipolar depression 

 HSMN NewsFeed - 11 Aug 2025
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Aug 2023
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101(TM) for Chronic Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Dec 2022
NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 18 Mar 2022
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Dec 2021
Healis Therapeutics announces mission to deliver new class of neuromuscular treatments in psychiatry
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 23 Oct 2019
NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Dec 2017
NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Sep 2017
NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 5 Aug 2016
Allergan and Richter Provide Update on Cariprazine Program
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 3 Dec 2014
Tal Medical Appoints Atul Pande, M.D., Former SVP and Head of Neurosciences at GSK, as Chief Medical Officer, EVP and SAB member
Devices Neurology Personnel
 HSMN NewsFeed - 28 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jun 2009
Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Mar 2009
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jun 2008
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Biopharmaceuticals
 HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2007
Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2007
Cephalon Provides Update Related to NUVIGIL(TM) New Drug Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Oct 2006
FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 May 2006
Second Investigational Study of SEROQUEL(R) in the Treatment of Depressive Episodes Associated with Bipolar Disorder Confirms Previous Findings
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
bipolar depression
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.